Pharsight

Alvesco patents expiration

ALVESCO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6036942 COVIS Seal configuration for aerosol canister
Apr, 2013

(11 years ago)

US5605674 COVIS Medicinal aerosol formulations
Feb, 2014

(10 years ago)

US5683677 COVIS Medicinal aerosol formulations
Nov, 2014

(9 years ago)

US5775321 COVIS Seal configuration for aerosol canister
Jul, 2015

(8 years ago)

US6006745 COVIS Device for delivering an aerosol
Dec, 2016

(7 years ago)

US5482934 COVIS Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
Oct, 2017

(6 years ago)

US6120752 COVIS Medicinal aerosol products containing formulations of ciclesonide and related steroids
May, 2018

(6 years ago)

US6264923 COVIS Medicinal aerosol formulation of ciclesonide and related compounds
May, 2018

(6 years ago)

US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(3 years from now)

Alvesco is owned by Covis.

Alvesco contains Ciclesonide.

Alvesco has a total of 9 drug patents out of which 8 drug patents have expired.

Expired drug patents of Alvesco are:

  • US6036942
  • US5605674
  • US5683677
  • US5775321
  • US6006745
  • US5482934
  • US6120752
  • US6264923

Alvesco was authorised for market use on 10 January, 2008.

Alvesco is available in aerosol, metered;inhalation dosage forms.

Alvesco can be used as maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child, method of treating inflammatory conditions.

Drug patent challenges can be filed against Alvesco from 20 October, 2010.

The generics of Alvesco are possible to be released after 01 February, 2028.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 20, 2011
M(M-125) Dec 17, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CICLESONIDE ingredient

NCE-1 date: 20 October, 2010

Market Authorisation Date: 10 January, 2008

Treatment: Method of treating inflammatory conditions; Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a resp...

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ALVESCO family patents

Family Patents